Supramolecular Hydrogels Encapsulating Bioengineered Mesenchymal Stem Cells for Ischemic Therapy
발표자
()
초록
내용
Mesenchymal stem cells (MSCs) have been widely investigated for therapeutic applications due to the advantageous characteristics of facile isolation, prolonged transgene expression and hypo-immunogenicity. Here, we developed a new platform of supramolecular hyaluronate (HA) hydrogels encapsulating genetically engineered MSCs (eMSCs) expressing enhanced green fluorescence protein (EGFP) as a model system, mutant interleukin-12 for cancer therapy and hepatocyte growth factor for ischemic therapy. The simple mixing of CB[6]-HA, DAH-HA and drug-CB[6] in the presence of eMSCs resulted in in situ hydrogel formation encapsulating eMSCs. The eMSCs producing EGFP remained alive and emitted the fluorescence within CB[6]/DAH-HA hydrogels in mice for more than 60 days. The long-term expression of protein by eMSCs within the supramolecular hydrogels resulted in effective inhibition of tumor growth and the enhanced recovery of blood perfusion in hind limb ischemic model mice.